Annovis Bio Statistics
Total Valuation
Annovis Bio has a market cap or net worth of $32.15 million. The enterprise value is $21.60 million.
Important Dates
The last earnings date was Friday, March 21, 2025, after market close.
Earnings Date | Mar 21, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Annovis Bio has 19.49 million shares outstanding. The number of shares has increased by 35.60% in one year.
Current Share Class | 19.49M |
Shares Outstanding | 19.49M |
Shares Change (YoY) | +35.60% |
Shares Change (QoQ) | +6.31% |
Owned by Insiders (%) | 14.45% |
Owned by Institutions (%) | 8.17% |
Float | 15.67M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 2.51 |
P/TBV Ratio | 3.45 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.59
Current Ratio | 3.59 |
Quick Ratio | 2.72 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -3,159.09% and return on invested capital (ROIC) is -2,143.41%.
Return on Equity (ROE) | -3,159.09% |
Return on Assets (ROA) | -138.26% |
Return on Invested Capital (ROIC) | -2,143.41% |
Return on Capital Employed (ROCE) | -265.76% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.54M |
Employee Count | 16 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.28% in the last 52 weeks. The beta is 1.65, so Annovis Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.65 |
52-Week Price Change | -86.28% |
50-Day Moving Average | 2.74 |
200-Day Moving Average | 6.61 |
Relative Strength Index (RSI) | 34.96 |
Average Volume (20 Days) | 272,781 |
Short Selling Information
The latest short interest is 1.88 million, so 9.64% of the outstanding shares have been sold short.
Short Interest | 1.88M |
Short Previous Month | 1.44M |
Short % of Shares Out | 9.64% |
Short % of Float | 11.99% |
Short Ratio (days to cover) | 4.34 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -26.69M |
Pretax Income | -47.53M |
Net Income | -24.59M |
EBITDA | n/a |
EBIT | -26.69M |
Earnings Per Share (EPS) | -$2.31 |
Full Income Statement Balance Sheet
The company has $10.55 million in cash and n/a in debt, giving a net cash position of $10.55 million or $0.54 per share.
Cash & Cash Equivalents | 10.55M |
Total Debt | n/a |
Net Cash | 10.55M |
Net Cash Per Share | $0.54 |
Equity (Book Value) | 9.31M |
Book Value Per Share | 0.66 |
Working Capital | 10.04M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -21.89M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Annovis Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -35.60% |
Shareholder Yield | -35.60% |
Earnings Yield | -76.48% |
FCF Yield | n/a |
Analyst Forecast
The average price target for Annovis Bio is $37.00, which is 2,142.42% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $37.00 |
Price Target Difference | 2,142.42% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |